Radiological pulmonary sequelae after COVID-19 and correlation with clinical and functional pulmonary evaluation: results of a prospective cohort
Objectives Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. Materials and methods We conducted a prospective single-center study among patients hospitalized for COVID-19 between March and May 2020. Patients with residual symptoms or admitted into intensive care units were investigated 4 months after discharge by a chest CT (CCT) and pulmonary function tests (PFTs). The primary endpoint was the rate of persistent radiological fibrotic lesions after 4 months. Secondary endpoints included further CCT evaluation at 9 and 16 months, correlation of fibrotic lesions with clinical and PFT evaluation, and assessment of predictive factors. Results Among the 1151 patients hospitalized for COVID-19, 169 patients performed a CCT at 4 months. CCTs showed pulmonary fibrotic lesions in 19% of the patients (32/169). These lesions were persistent at 9 months and 16 months in 97% (29/30) and 95% of patients (18/19) respectively. There was no significant clinical difference based on dyspnea scale in patients with pulmonary fibrosis. However, PFT evaluation showed significantly decreased diffusing lung capacity for carbon monoxide (p < 0.001) and total lung capacity (p < 0.001) in patients with radiological lesions. In multivariate analysis, the predictive factors of radiological pulmonary fibrotic lesions were pulmonary embolism (OR = 9.0), high-flow oxygen (OR = 6.37), and mechanical ventilation (OR = 3.49). Conclusion At 4 months, 19% of patients investigated after hospitalization for COVID-19 had radiological pulmonary fibrotic lesions; they persisted up to 16 months. Clinical relevance statement Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. The prevalence of persisting lesions after COVID-19 remains unclear. We assessed this prevalence and predictive factors leading to fibrotic lesions in a large cohort. The respiratory clinical impact of these lesions was also assessed. Key Points • Nineteen percent of patients hospitalized for COVID-19 had radiological fibrotic lesions at 4 months, remaining stable at 16 months. • COVID-19 fibrotic lesions did not match any infiltrative lung disease pattern. • COVID-19 fibrotic lesions were associated with pulmonary function test abnormalities but did not lead to clinical respiratory manifestation..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
---|---|
Enthalten in: |
European radiology - 34(2023), 2 vom: 12. Aug., Seite 1037-1052 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Soliman, Samer [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s00330-023-10044-0 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR054687896 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR054687896 | ||
003 | DE-627 | ||
005 | 20240209064639.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240209s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00330-023-10044-0 |2 doi | |
035 | |a (DE-627)SPR054687896 | ||
035 | |a (SPR)s00330-023-10044-0-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Soliman, Samer |e verfasserin |0 (orcid)0000-0002-8827-115X |4 aut | |
245 | 1 | 0 | |a Radiological pulmonary sequelae after COVID-19 and correlation with clinical and functional pulmonary evaluation: results of a prospective cohort |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Objectives Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. Materials and methods We conducted a prospective single-center study among patients hospitalized for COVID-19 between March and May 2020. Patients with residual symptoms or admitted into intensive care units were investigated 4 months after discharge by a chest CT (CCT) and pulmonary function tests (PFTs). The primary endpoint was the rate of persistent radiological fibrotic lesions after 4 months. Secondary endpoints included further CCT evaluation at 9 and 16 months, correlation of fibrotic lesions with clinical and PFT evaluation, and assessment of predictive factors. Results Among the 1151 patients hospitalized for COVID-19, 169 patients performed a CCT at 4 months. CCTs showed pulmonary fibrotic lesions in 19% of the patients (32/169). These lesions were persistent at 9 months and 16 months in 97% (29/30) and 95% of patients (18/19) respectively. There was no significant clinical difference based on dyspnea scale in patients with pulmonary fibrosis. However, PFT evaluation showed significantly decreased diffusing lung capacity for carbon monoxide (p < 0.001) and total lung capacity (p < 0.001) in patients with radiological lesions. In multivariate analysis, the predictive factors of radiological pulmonary fibrotic lesions were pulmonary embolism (OR = 9.0), high-flow oxygen (OR = 6.37), and mechanical ventilation (OR = 3.49). Conclusion At 4 months, 19% of patients investigated after hospitalization for COVID-19 had radiological pulmonary fibrotic lesions; they persisted up to 16 months. Clinical relevance statement Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. The prevalence of persisting lesions after COVID-19 remains unclear. We assessed this prevalence and predictive factors leading to fibrotic lesions in a large cohort. The respiratory clinical impact of these lesions was also assessed. Key Points • Nineteen percent of patients hospitalized for COVID-19 had radiological fibrotic lesions at 4 months, remaining stable at 16 months. • COVID-19 fibrotic lesions did not match any infiltrative lung disease pattern. • COVID-19 fibrotic lesions were associated with pulmonary function test abnormalities but did not lead to clinical respiratory manifestation. | ||
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pulmonary fibrosis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Chest computed tomography |7 (dpeaa)DE-He213 | |
650 | 4 | |a Lung sequelae |7 (dpeaa)DE-He213 | |
700 | 1 | |a Soliman, Heithem |4 aut | |
700 | 1 | |a Crézé, Maud |4 aut | |
700 | 1 | |a Brillet, Pierre-Yves |4 aut | |
700 | 1 | |a Montani, David |4 aut | |
700 | 1 | |a Savale, Laurent |4 aut | |
700 | 1 | |a Jais, Xavier |4 aut | |
700 | 1 | |a Bulifon, Sophie |4 aut | |
700 | 1 | |a Jutant, Etienne-Marie |4 aut | |
700 | 1 | |a Rius, Emily |4 aut | |
700 | 1 | |a Devilder, Matthieu |4 aut | |
700 | 1 | |a Beurnier, Antoine |4 aut | |
700 | 1 | |a Colle, Romain |4 aut | |
700 | 1 | |a Gasnier, Matthieu |4 aut | |
700 | 1 | |a Pham, Tài |4 aut | |
700 | 1 | |a Morin, Luc |4 aut | |
700 | 1 | |a Noel, Nicolas |4 aut | |
700 | 1 | |a Lecoq, Anne-Lise |4 aut | |
700 | 1 | |a Becquemont, Laurent |4 aut | |
700 | 1 | |a Figueiredo, Samy |4 aut | |
700 | 1 | |a Harrois, Anatole |4 aut | |
700 | 1 | |a Bellin, Marie-France |4 aut | |
700 | 1 | |a Monnet, Xavier |4 aut | |
700 | 1 | |a Meyrignac, Olivier |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European radiology |d Berlin : Springer, 1991 |g 34(2023), 2 vom: 12. Aug., Seite 1037-1052 |w (DE-627)SPR00395112X |w (DE-600)1472718-3 |x 1432-1084 |7 nnns |
773 | 1 | 8 | |g volume:34 |g year:2023 |g number:2 |g day:12 |g month:08 |g pages:1037-1052 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00330-023-10044-0 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 34 |j 2023 |e 2 |b 12 |c 08 |h 1037-1052 |